I don’t know why anyone would want to buy AT&T (NYSE:T) stock. Source: Roman Tiraspolsky / Shutterstock.com The moves into content by former CEO Randall Stephenson bombed spectacularly. Shareholders are left with $177 billion in debt and, starting next year, a skinnier dividend. The company’s wireless prospects are decent, but only because it can rip
0 Comments
Coinbase (NASDAQ:COIN) stock enjoys the first-mover advantage with cryptocurrency and has taken crypto mainstream with its user-friendly investment platform. Source: Primakov / Shutterstock.com Bitcoin (CCC:BTC-USD) has attracted massive interest and investment over the last few months. Investors have high hopes on Bitcoin’s price movement, which has driven BTC higher and it has worked in favor
0 Comments
Financial markets love nice round numbers. In early August, COMEX gold futures crossed $2,000 dollars per troy ounce of gold for the first time ever, with the nearby COMEX GC contract for August delivery settling at $2,001. The December 2020 delivery contract reached a price of $2,069 on August 6, before the market came back
0 Comments
With a bipartisan infrastructure bill and a $3.5 trillion budget resolution making their way through Congress and looking poised to pass, I believe investors are greatly underestimating the extent to which these pieces of legislation will help General Electric (NYSE:GE) and GE stock. Source: Sundry Photography / Shutterstock.com GE operates through four industrial segments — Power,
0 Comments
Workhorse Group (NASDAQ:WKHS) hoped to revolutionize the trucking industry. However, WKHS stock has turned into a total bust over the past year. Shares peaked at $42 in February, but have now fallen below $10 for a greater than 75% loss. Source: Shutterstock Workhorse is part of a broader exodus from the electric vehicle stocks. Investors
0 Comments
Cassava Sciences (NASDAQ:SAVA) stock is in a tailspin after a lab denied it had prepared recent results for the biotech’s experimental Alzheimer’s disease treatment. Source: pathdoc / Shutterstock.com Following the news, Cassava shares fell approximately 50%, eliminating roughly $2.4 billion of value over three trading days. The rejection contradicts a statement from Cassava that Quanterix
0 Comments
It’s been a little more than three weeks since Zomedica (NYSEAMERICAN:ZOM) reported its Q2 results. Despite reasonably healthy sales, ZOM stock gained just 14% from Aug. 11 through the end of the month.  Source: Postmodern Studio / Shutterstock.com Another InvestorPlace columnist, Ian Bezek, recently argued that Zomedica needs to raise its revenues considerably before investors
0 Comments